CA
NZ
UK
AU
IND
US
Positive Momentum for Strata Critical Medical (NASDAQ: SRTA) Shares
The surge propelled the firm into profitability with net income of $250,242, a stark contrast to the $63,596 loss a year earlier. The momentum suggests the company may sustain its upward trajectory as it chases full‑year profitability.
Truist has raised RadNet's stock price target to $94, reflecting confidence in the company's strong performance. This adjustment may attract investor interest, signaling a favorable outlook for future growth.Key HighlightsTruist increased RadNet's price target to $94, up from previous estimates.The adjustment comes on the …
Intensity Therapeutics (NASDAQ: INTS) reportedEarnings Per Shareof $-0.96 for its most recent quarter, improving on consensus expectations. The company’s cash and cash equivalents total $9.5 million, providing a runway for its late‑stage oncology initiatives. Management emphasized the restart of enrollment in the Phase 3 …
LB Pharmaceuticals Inc posted an EPS of $-0.67 for the quarter ended June 30, 2026, outperforming analyst expectations of $-0.76. This performance signals potential growth in the company’s innovative pipeline, making it an interesting opportunity for investors.Key HighlightsThe company’s shares have soared 126.4% year-to-date, …
Analyst Forecast Indicates Growth Potential for Merck
Three S&P 500 medical‑sector equities are now hovering at analyst‑set buy points, while a fourth defied a mixed earnings backdrop to climb higher. The pattern sparked activity across health‑care ETFs and prompted traders to rebalance exposure ahead of upcoming earnings windows.Market Breadthstayed modest, but …
Three S&P 500 medical‑sector equities are now hovering at analyst‑set buy points, while a fourth defied a mixed earnings backdrop to climb higher. The pattern sparked activity across health‑care ETFs and prompted traders to rebalance exposure ahead of upcoming earnings windows.Market Breadthstayed modest, but …
Bionano Genomics Inc. (NASDAQ: BNGO) reported second‑quarter revenue of $8.2 million, a 21% jump from $6.7 million a year earlier, whileEarnings Per Sharebeat consensus at $‑0.64 versus $‑0.70. The company also retired all outstanding senior secured convertible debentures, eliminating a notable source of financing …
CalciMedica has reported a net loss of $7.7 million for the quarter ending June 30, 2026, signaling continued financial challenges. Investors will focus on the upcoming Phase 1b trial results in mid-2027, which could pivot the company's growth trajectory.Key HighlightsCalciMedica completed a $49 million …
Please wait processing your request...